Some cannabinoids are known to have anti-inflammatory effects, and would seem therefore to be of promise in controlling conditions like acute respiratory distress syndrome. Of particular interest is cannabichromene (CBC).
In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time,show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream.
In parallel to the body’s endocannabinoid neural signaling network, there exists an endo-opioid system (the one responsible for runners’ high), and the two systems communicate. This suggests an expanded pharmacological strategy for treating opioid dependence.
PureForm Global announces that Cellular Goods, a UK-based wellness company providing premium consumer products formulated with lab-produced cannabinoids, has launched its first products formulated with PureForm CBD™.
Evidence is that CBD may ameliorate psychotic symptoms, with a superior side-effect profile than established antipsychotics, in patients with schizophrenia and in sufferers of psychosis induced by long-term use of THC.